Can-Fite BioPharma (NYSE:CANF) Ltd. (NYSE American: CANF) today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the...
Can-Fite BioPharma (CANF) reported Q3 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $613 thousand versus the consensus...
This week, the biotech sector was in focus with updates from biotechs evaluating their pipeline drugs and vaccines for the treatment of COVID-19. A new strain of coronavirus, which...
Can-Fite BioPharma Ltd. (NYSE:CANF) announced that data from the interim analysis of the phase III study on lead candidate, piclidenoson, will be released during the fourth...
Shares of Can-Fite BioPharma Ltd. (NYSE:CANF) surged 12.8% after the company announced pre-clinical data from the Hadassah Medical Center lab reveal that Namodenoson induces...
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
| Average | 40.833 (+1,722.915% Upside) |
| High | 82.500 |
| Low | 6.000 |
| Price | 2.240 |
| No. of Analysts | 3 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 22.82 | 23.10 | 22.80 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 12.26 | 12.97 | 12.13 | -0.71 | -5.47% | 7.45M | NASDAQ | |||
| 15.62 | 15.97 | 15.60 | -0.11 | -0.70% | 816.35K | NYSE | |||
| 25.00 | 25.00 | 24.99 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 10.03 | 10.11 | 9.99 | 0.00 | 0.00% | 455.08K | NASDAQ | |||
| 110.16 | 114.55 | 109.31 | -3.69 | -3.24% | 790.07K | NYSE | |||
| 0.0004 | 0.0005 | 0.0004 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 42.38 | 43.71 | 42.16 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 10.02 | 10.31 | 9.93 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 0.0001 | 0.0001 | 0.0001 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 0.0019 | 0.0029 | 0.0019 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 0.006 | 0.007 | 0.006 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 17.27 | 17.72 | 16.78 | -0.07 | -0.40% | 1.08M | NASDAQ | |||
| 8.89 | 8.93 | 8.695 | +0.250 | +2.89% | 1.17M | NYSE | |||
| 1.61 | 1.61 | 1.61 | 0.00 | 0.00% | 0.00 | OTC Markets |